Alkermes Jumps on License Deal With Biogen -- Biotech Movers
The agreement gives Cambridge, Mass.-based Biogen an exclusive, worldwide license to commercialize ALKS 8700. Biogen will pay Alkermes a mid-teens royalty on worldwide net sales of the drug.
from Biotech News
0 Comments